Aug. 7 at 2:47 PM
$LEXX Assuming the unblinded trial data hits the wire between late August and mid-September as scheduled, the most probable outcome by the end of September is the Base Case (
$12.00 –
$18.00 / share). The low float is primed for a volume-driven re-rate—it just needs the unblinded CRO lab reports to serve as the fundamental spark.
The Bull Case (Data Spike + Pharma MTA Conversion)
Target Range:
$30.00 –
$60.00+ / share (Market Cap: ~
$50M –
$100M+)

Unblinded data exceeds expectations, and "PharmaCO" exercises its option under the Material Transfer Agreement (MTA) or signs an expanded licensing deal with upfront cash.
The Drivers:
1. Securing non-dilutive capital (
$10M–
$20M upfront) completely eliminates near-term insolvency risk.
2. Wall Street re-values DehydraTECH as an essential oral delivery vehicle for Big Pharma's multi-billion-dollar GLP-1 pipeline.
3. Low-float squeeze mechanics push the order book into aggressive price discovery.
